Professor of Medicine
Consultant in thoracic & general medicine
Consultant in HIV/AIDS medicine
Professor Johnson is a leading consultant in respiratory medicine with over 20 years experience working in the field.
Professor Johnson is also one of the UK's leading consultants in HIV medicine. She has a special interest in HIV infection; diagnosing, treating clinical complications of HIV and antiretroviral therapy.
Professor Johnson set up the first and largest open-access HIV testing clinc in the UK and has started the first specific clinic for women with HIV infection.
- Selected publications
- Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C, Dunn DT; UK HIV Drug Resistance Database and UK CHIC Study . Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. J Antimicrob Chemother. 2018. [Epub ahead of print]
- Sabin CA, Harding R, Bagkeris E, Nkhoma K, Post FA, Sachikonye M, Boffito M, Anderson J, Mallon PWG, Williams I, Vera J, Johnson M, Babalis D, Winston A. Pain in people living with HIV and its association with healthcare resource use, well being and functional status. AIDS. 2018. 32(18):2697-2706
- Haddow LJ, Godi C, Sokolska M, Cardoso MJ, Oliver R, Winston A, Stöhr W, Clarke A, Chen F, Williams IG, Johnson M, Paton N, Arenas-Pinto A, Golay X, Jäger HR. Brain perfusion, regional volumes and cognitive function in HIV positive patients treated with protease inhibitor monotherapy. Clin Infect Dis. 2018. [Epub ahead of print]
- Jose S, Delpech V, Howarth A, Burns F, Hill T, Porter K, Sabin CA; UK CHIC Study Steering Committee. A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. Lancet HIV. 2018. 5(6):e301-e308
- Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017. 31(18):2503-2514
- Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus Nordwall J, Johnson M, Vjecha MJ, Kelleher AD, Emery S. Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. Sci Rep. 2017. 7(1):10934
- O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, Dunn D, Winston A, Post FA, Sabin C, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017. 4(7):e295-e302
- Lewis JM, Smith C, Torkington A, Davies C, Ahmad S, Tomkins A, Shaw J, Kingston M, Muqbill G, Hay P, Mulka L, Williams D, Waters L, Brima N, Marshall N, Johnson M, Chaponda M, Nelson M. Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study. J Infect. 2017. 74(4):401-407
- Burch LS, Smith CJ, Anderson J, Sherr L, Rodger AJ, O'Connell R, Geretti AM, Gilson R, Fisher M, Elford J, Jones M, Collins S, Azad Y, Phillips AN, Speakman A, Johnson MA, Lampe FC. Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. Lancet Public Health. 2016. 1(1):e26-e36
- Borges ÁH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugyenyi P, Domingo P, Hoffmann C, Read TR, Pujari S, Meulbroek M, Johnson M, Wilkin T, Mitsuyasu R; INSIGHT START Study Group. Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. Clin Infect Dis. 2016. 63(12):1668-1676.